X0508 4 2025-12-12 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742485 Kumar Neil C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250 PALO ALTO CA 94304 1 1 0 0 Chief Executive Officer 1 Common Stock 2025-12-12 4 M 0 60975 A 289751 D Common Stock 2025-12-12 4 F 0 30964 75.15 D 258787 D Common Stock 2025-12-15 4 S 0 28311 74.5997 D 230476 D Common Stock 2025-12-15 4 S 0 1700 75.2412 D 228776 D Common Stock 755686 I By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Common Stock 4558447 I By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Restricted Stock Units 2025-12-12 4 M 0 60975 0 D Common Stock 60975 60976 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 60,975 shares of Common Stock underlying the Reporting Person's RSUs. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $74.12 to $75.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $75.13 to $75.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. /s/ Will Solis, Attorney-in-Fact 2025-12-16